Glofitamab with CAR-T cell therapy for large B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding a drug called glofitamab before and after CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) can improve outcomes for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if this combination can help you stay in remission longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a type of large B-cell lymphoma (a cancer of the lymph system) and have had it come back or not respond to your first treatment.
- Your first treatment for lymphoma must have included a combination called R-CHOP (or a similar regimen with a CD20 antibody and an anthracycline).
- You must be considered eligible for CAR-T cell therapy (a type of treatment using your own immune cells) and have already had the cell collection procedure (leukapheresis).
- You need to have at least one tumor that can be measured on a CT or PET scan, and be in fair overall health (able to do light activities).
- Your kidney, liver, bone marrow, heart, and lung function must meet certain minimum levels for safety.
- You cannot have certain infections (like HIV), active autoimmune disease, or a history of lymphoma in the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a targeted antibody treatment called glofitamab with radiation therapy for people whose diffuse large B-cell lymphoma has come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
Hear when a new Relapsed /Refractory DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.